Combined Liver Stiffness and Α-fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis C
Table 2
Cox regression analysis for prediction of LREs (n = 23, multivariate analysis) after a sustained virologic response.
Variables
n/n
Crude HR
(95%CI)
value
Adjusted HR
(95% CI)
value
Age, ≥65 vs. <65 years (TW0)
28/514
1.068
1.028–1.109
<0.001
2.882
1.187–6.996
0.019
Sex, male vs female
28/514
0.776
0.369–1.633
0.504
Body mass index, kg/m2 (TW0)
28/514
1.076
0.972–1.191
0.159
HCV RNA log10, IU/mL (TW0)
28/514
1.000
1.000–1.000
0.265
Genotype, 1 vs non-1
28/514
1.245
0.583–2.660
0.572
Clinical cirrhosis (TW0)
28/520
1.817
0.688–4.795
0.228
AST, U/L (TW0)
28/511
1.006
1.002–1.010
0.005
ALT, U/L (TW0)
28/514
1.003
0.999–1.006
0.168
AFP, ng/mL (TW0)
28/504
0.999
0.992–1.006
0.851
Albumin, g/dL (TW0)
28/504
0.316
0.136–0.736
0.008
Bilirubin, mg/dL (TW0)
28/513
1.458
0.587–3.621
0.417
eGFR, mL/min/1.73 m2 (TW0)
28/514
0.994
0.985–1.004
0.243
HbA1c, % (TW0)
27/498
1.166
0.845–1.609
0.351
WBCs, /μL (TW0)
28/514
1.000
1.000–1.000
0.823
Hemoglobin, g/dL (TW0)
28/514
0.768
0.596–0.989
0.041
Platelets, ×103/μL (TW0)
28/514
0.989
0.982–0.997
0.004
INR (TW0)
28/513
1.062
0.043–26.14
0.970
AST, U/L (SVR)
28/512
1.019
1.011–1.028
<0.001
ALT, U/L (SVR)
28/514
1.013
1.004–1.021
0.004
0.996
0.979–1.014
0.667
AFP, ng/mL (SVR)
28/502
1.048
1.030–1.067
<0.001
1.026
1.000–1.052
0.039
Albumin, g/dL (SVR)
28/505
0.333
0.130–0.854
0.022
0.685
0.251–1.872
0.461
Bilirubin, mg/dL (SVR)
28/510
1.382
0.541–3.529
0.498
1.881
0.694–5.100
0.214
eGFR, mL/min/1.73 m2 (SVR)
28/505
0.992
0.982–1.002
0.130
HbA1c, % (SVR)
27/471
1.112
0.740–1.672
0.608
WBC, /μL (SVR)
28/511
1.000
1.000–1.000
0.076
Hemoglobin, g/dL (SVR)
28/512
0.795
0.624–1.012
0.062
Platelet, ×103/μL (SVR)
28/512
0.986
0.979–0.994
<0.001
0.996
0.987–1.004
0.311
INR (SVR)
28/487
12.222
1.037–144
0.047
LS, m/s (TW0)
24/376
2.745
1.661–4.536
<0.001
LS, m/s (SVR)
23/356
2.954
1.888–4.621
<0.001
2.398
1.350–4.260
0.003
APRI (TW0)
28/511
1.236
1.086–1.408
0.001
APRI (SVR)
28/510
1.879
1.511–2.336
<0.001
FIB-4 (TW0)
28/511
1.203
1.104–1.311
<0.001
FIB-4 (SVR)
28/510
1.375
1.243–1.521
<0.001
n/n indicates the number of events and the sample size (cases with missing values were excluded; six cases were censored before the first event after SVR; 350 cases entered the multivariate analysis). AFP, α-fetoprotein; ALT, alanine aminotransferase; APRI, aspartate-aminotransferase-to-platelet ratio index; AST, aspartate aminotransferase; CI, confidence interval; eGFR, estimated glomerular filtration rate (modification of diet in renal disease formula); FIB-4, fibrosis-4 index; HbA1c, hemoglobin A1c; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio; INR, international normalized ratio; LRE, liver-related event; LS, liver stiffness; SVR, sustained virologic response (visit); TW0, treatment baseline; WBC, white blood cell.
